PM8002 plus chemo for untreated metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your colorectal cancer must be metastatic (stage IV) and cannot be removed by surgery.
- Your tumor must not be MSI-H or dMMR (a specific genetic type).
- You cannot have had any prior chemotherapy or targeted therapy for metastatic disease.
- You must be in reasonably good health (able to perform daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.